PF-610355

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable^[1] ultra-long-acting β₂ adrenoreceptor agonist^[2] (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer.^[3] It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically mediated adverse events.^[4] Its in vivo duration on action confirmed its potential for once-daily use in humans.^[5]

Routes of
administrationInhalation

ATC code

• None

Legal status

• Development terminated

CAS Number

• 862541-45-5

Quick facts Clinical data, Routes ofadministration ...

PF-610355

Clinical data
Routes of administration	Inhalation
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide
CAS Number	862541-45-5
PubChem CID	11505444
ChemSpider	9680243 Y
UNII	ZH5SMU97AJ
ChEMBL	ChEMBL1240967 Y
CompTox Dashboard (EPA)	DTXSID501099960
Chemical and physical data
Formula	C34H39N3O6S
Molar mass	617.76 g·mol−1

Close

The investigation and development of PF-610355 were discontinued in 2011,^[6] likely for strategic and regulatory reasons.^[7]